Advertisement

Halogenation of N(6)-benzyladenosine decreases its cytotoxicity in human leukemia cells.

01:27 EDT 20th May 2013 | BioPortfolio

Summary of "Halogenation of N(6)-benzyladenosine decreases its cytotoxicity in human leukemia cells."

Cytotoxicity of two halogen derivatives of N(6)-benzyladenosine (BAPR), N(6)-(3-iodobenzyl)-adenosine (I-BAPR) and 2-chloro-N(6)-(3-iodobenzyl)-adenosine (Cl-I-BAPR), was tested in human leukemia U937 cell line. Our results revealed that their cytotoxicity was surprisingly low. I-BAPR and also Cl-I-BAPR induced cell death with morphological and biochemical hallmarks of apoptosis, although the number of apoptotic cells was significantly lower than that found for BAPR. Our data strongly suggested that the decreased cytotoxic effect of halogenated derivatives of N(6)-benzyladenosine was related to their reduced intracellular phosphorylation by adenosine kinase.

Affiliation

Department of Biology, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 3, Olomouc 77515, Czech Republic.

Journal Details

This article was published in the following journal.

Name: Toxicology in vitro : an international journal published in association with BIBRA
ISSN: 1879-3177
Pages:

Links

Medical and Biotech [MESH] Definitions

Kirsten Murine Sarcoma Virus

A replication-defective murine sarcoma virus (SARCOMA VIRUSES, MURINE) capable of transforming mouse lymphoid cells and producing erythroid leukemia after superinfection with murine leukemia viruses (LEUKEMIA VIRUS, MURINE). It has also been found to transform cultured human fibroblasts, rat liver epithelial cells, and rat adrenocortical cells.

Abelson Murine Leukemia Virus

A replication-defective strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) capable of transforming lymphoid cells and producing a rapidly progressing lymphoid leukemia after superinfection with FRIEND MURINE LEUKEMIA VIRUS; MOLONEY MURINE LEUKEMIA VIRUS; or RAUSCHER VIRUS.

Philadelphia Chromosome

An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE).

Deltaretrovirus

A genus in the family RETROVIRIDAE consisting of exogenous horizontally-transmitted viruses found in a few groups of mammals. Infections caused by these viruses include human B- or adult T-cell leukemia/lymphoma (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), and bovine leukemia (ENZOOTIC BOVINE LEUKOSIS). The type species is LEUKEMIA VIRUS, BOVINE.

Carbazilquinone

An alkylating agent structurally similar to MITOMYCIN and found to be effective in the treatment of leukemia and various other neoplasms in mice. It causes leukemia and thrombocytopenia in almost all human patients.

PubMed Articles [ 26464 Associated PubMed Articles listed on BioPortfolio]

Decarbonylative halogenation by a vanadium complex.

Metal-catalyzed halogenation of the C-H bond and decarbonylation of aldehyde are conventionally done in nature. However, metal-mediated decarbonylative halogenation is unknown. We have developed the f...

CD99 ligation upregulates HSP70 on acute lymphoblastic leukemia cells and concomitantly increases NK cytotoxicity.

CD99 is present in many human cell types, including high-level surface expression on pediatric B and T leukemias and Ewing tumors (ETs). On B lymphocytes and respective malignancies, its level decreas...

The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells.

Abstract Background aims. Cytokine-induced killer (CIK) cells may serve as an alternative approach to adoptive donor lymphocyte infusions (DLI) for patients with acute leukemia relapsing after haplo...

Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells.

A major advancement in the treatment of chronic myeloid leukemia (CML) has been the development of imatinib and other BCR-ABL tyrosine kinase inhibitors. MicroRNAs (miRNAs) are small RNA molecules tha...

Acute myeloid leukemia cells fail to activate native human dendritic cells: a potential mechanism of immune evasion.

Clinical Trials [ 5848 Associated Clinical Trials listed on BioPortfolio]

A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia

Ofatumumab is an IgG1κ fully human monoclonal antibody (mAb) that specifically recognizes an epitope on the human differentiation antigen CD20 molecule. In vitro and in vivo studies demon...

ZRx-101 (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia

The ZRx-101 cells have features similar to activated NK cells, but mediate superior anti-tumor activity against hematologic and solid tumor targets in vitro and in vivo. The utilization of...

Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells

The purpose of this study is to learn the safety and cancer-fighting effects of using IL-2 with the vaccines ("shots") made for you.

Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects

Ofatumumab is a fully-human monoclonal antibody that exhibits high binding affinity to an antigen on the surface of B lymphocytes. Antigen engagement by ofatumumab results in maximal B-ce...

Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

This study will test the ability of a specially designed monoclonal antibody to destroy multiple myeloma cells. This antibody is unique in its ability to promote the death of multiple my...

Search BioPortfolio: